65,437 trials
Depressive Disorder, Major
Primary: Change From Baseline in Hamilton Depression Scale (HAM-D) at Week 12 — -12.61; -10.50 Scores on a scale — p=0.002
Lymphoma, Non-Hodgkin · Multiple Myeloma
Primary: Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE) — 23; 26; 49; 8 participants
Hepatitis B, Chronic · Chronic Hepatitis B
Primary: Hepatitis B Virus (HBV) DNA (log10 Copies/mL) Change From Baseline at Week 156 of Adefovir Therapy — 7.94; 3.89; -4.16 log10 copies/mL — p=<0.001
Parkinson Disease
Primary: Proportion of Adverse Events, Adverse Drug Reactions, Serious Adverse Events — 42.4; 34.5; 7.2 percentage of participants
Parkinson Disease
Primary: Proportion of Adverse Events, Adverse Drug Reactions, Serious Adverse Events — 51.7; 41.3; 8.4 Proportion (percentage of participants)
Asthma
Primary: FEV1 AUC0-6 Response (Crossover Part of the Study) — 0.167; 0.252 liters — p=<0.0001
Allergic Conjunctivitis
Primary: Lid and Lid Margin Erythema, Change From Baseline — 0; 0 Units on a scale
ADHD
Primary: Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 8 - Last Observation Carried Forward (LOCF)…
Allergic Conjunctivitis
Primary: Lid and Lid Margin Erythema, Change From Baseline — 0; 0 Units on a scale
Partial Epilepsies
Primary: Number of Subjects Reporting at Least 1 Treatment-Emergent Adverse Event (TEAE) During the Treatment Period (Maximum 6 Years) — 288 subjects
Healthy
Primary: Mean Percent Time That Gastric pH > 4.0 on Day 5 — 36.8; 45.7 percent time gastric pH exceeds 4.0 — p=< 0.0001
Migraine
Primary: Pain Freedom (PF) — 13; 4; 5; 16 Participants — p=<0.001
Overactive Bladder Syndrome
Primary: Numerical Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Week 12 — -3.2; -2.9 number of episodes — p=0.1959
Acne Vulgaris
Primary: Subject Reported Change From Baseline Scale — 0; 0; 7; 6 Participants
Thrombocytopenia · MDS · Myelodysplastic Syndromes
Primary: Part A: Number of Participants With Adverse Events — 6; 11; 11; 15 Participants